Meta-analysis of faricimab (Vabismo) in retinal diseases: Insights from the last decade

Abstract

Faricimab (Vabismo), a bispecific antibody developed by Roche, is designed to target both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) simultaneously. This meta-analysis aims to consolidate findings from research conducted over the past decade to assess faricimab’s clinical efficacy, safety, and comparative effectiveness in treating retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). We examined clinical trials, real-world evidence, and comparative studies to provide a thorough evaluation of faricimab’s role in retinal disease management.